Metastatic Male Breast Cancer: a Retrospective Cohort Analysis

Overview

Journal Breast Care (Basel)

Publisher Karger

Date 2014 Nov 19

PMID 25404886

Citations 9

Authors

Robert Foerster

Lars Schroeder

Frank Foerster

Volker Wulff

Birgit Schubotz

Dieter Baaske

Christian Rudlowski

Affiliations

Soon will be listed here.

Abstract

Background: Metastasized male breast cancer (MMBC) is a rare disease. Given its low incidence, data regarding tumor biology, current treatment options, and survival rates are scarce.

Patients And Methods: A chart review was performed of MMBC patients consecutively registered in regional cancer registries in Germany between 1995 and 2011. Tumor characteristics, treatment, and survival rates were documented and statistically evaluated.

Results: 41 men with MMBC represented 25.6% of a total of 160 patients with MBC. 16 (39%) patients showed primary metastases, and 25 (61%) had recurrent metastases. Median survival from occurrence of metastasis was 32 months. Median overall survival (OS) was 68 months. 68.3% (n = 28) of the cohort received systemic therapy favoring endocrine therapy (n = 25, 61.9%). Prolonged metastatic OS (p = 0.02) was observed in patients having had a systemic treatment. Metastatic patients having received endocrine treatment showed significantly prolonged survival rates. Furthermore, patients receiving palliative chemotherapy had a significant survival benefit compared to those in whom chemotherapy was omitted.

Conclusion: Our results suggest that systemic treatment in the form of both palliative chemotherapy and endocrine therapy improves outcome of R. Foerster and L. Schroeder contributed equally to this article and are listed in alphabetical order. MMBC. Therefore, it seems reasonable that treatment of MMBC should be based on the guidelines for female breast cancer.

Citing Articles

Unexpected and Rare Sites of Metastasis in Oncologic Patients.

Shalata W, Abu Jama A, Abu Salman A, Golosky M, Solomon A, Abu Saleh O J Clin Med. 2023; 12(20).

PMID: 37892585 PMC: 10607747. DOI: 10.3390/jcm12206447.

Male Breast Cancer Review. A Rare Case of Pure DCIS: Imaging Protocol, Radiomics and Management.

Tari D, Morelli L, Guida A, Pinto F Diagnostics (Basel). 2021; 11(12).

PMID: 34943439 PMC: 8700459. DOI: 10.3390/diagnostics11122199.

Mammary Tumorigenesis and Metabolome in Male Adipose Specific Monocyte Chemotactic Protein-1 Deficient MMTV-PyMT Mice Fed a High-Fat Diet.

Yan L, Sundaram S, Rust B, Picklo M, Bukowski M Front Oncol. 2021; 11:667843.

PMID: 34568008 PMC: 8458874. DOI: 10.3389/fonc.2021.667843.

Management and outcome of male metastatic breast cancer in the national multicenter observational research program Epidemiological Strategy and Medical Economics (ESME).

Sirieix J, Fraisse J, Mathoulin-Pelissier S, Leheurteur M, Vanlemmens L, Jouannaud C Ther Adv Med Oncol. 2021; 12:1758835920980548.

PMID: 33488779 PMC: 7768846. DOI: 10.1177/1758835920980548.

Breast cancer in men: a serie of 45 cases and literature review.

Methamem M, Ghadhab I, Hidar S, Briki R Pan Afr Med J. 2020; 36:183.

PMID: 32952827 PMC: 7467624. DOI: 10.11604/pamj.2020.36.183.22574.

References

Korde L, Zujewski J, Kamin L, Giordano S, Domchek S, Anderson W . Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol. 2010; 28(12):2114-22. PMC: 2860409. DOI: 10.1200/JCO.2009.25.5729. View

Gennari R, Curigliano G, Jereczek-Fossa B, Zurrida S, Renne G, Intra M . Male breast cancer: a special therapeutic problem. Anything new? (Review). Int J Oncol. 2004; 24(3):663-70. View

Anderson W, Jatoi I, Tse J, Rosenberg P . Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol. 2009; 28(2):232-9. PMC: 2815713. DOI: 10.1200/JCO.2009.23.8162. View

Eggemann H, Ignatov A, Smith B, Altmann U, von Minckwitz G, Rohl F . Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Res Treat. 2012; 137(2):465-70. DOI: 10.1007/s10549-012-2355-3. View

Kantarjian H, Yap H, Hortobagyi G, Buzdar A, Blumenschein G . Hormonal therapy for metastatic male breast cancer. Arch Intern Med. 1983; 143(2):237-40. View

Lopez M, Di Lauro L, Papaldo P, Lazzaro B . Chemotherapy in metastatic male breast cancer. Oncology. 1985; 42(4):205-9. DOI: 10.1159/000226032. View

Giordano S, Buzdar A, Smith T, Kau S, Yang Y, Hortobagyi G . Is breast cancer survival improving?. Cancer. 2003; 100(1):44-52. DOI: 10.1002/cncr.11859. View

Chavez-MacGregor M, Clarke C, Lichtensztajn D, Hortobagyi G, Giordano S . Male breast cancer according to tumor subtype and race: a population-based study. Cancer. 2013; 119(9):1611-7. PMC: 3971835. DOI: 10.1002/cncr.27905. View

Anderson W, Althuis M, Brinton L, Devesa S . Is male breast cancer similar or different than female breast cancer?. Breast Cancer Res Treat. 2004; 83(1):77-86. DOI: 10.1023/B:BREA.0000010701.08825.2d. View

10.

Rudlowski C, Rath W, Becker A, Wiestler O, Buttner R . Trastuzumab and breast cancer. N Engl J Med. 2001; 345(13):997-8. View

11.

Agrawal A, Cheung K, Robertson J . Fulvestrant in advanced male breast cancer. Breast Cancer Res Treat. 2006; 101(1):123. DOI: 10.1007/s10549-006-9266-0. View

12.

Foerster R, Foerster F, Wulff V, Schubotz B, Baaske D, Wolfgarten M . Matched-pair analysis of patients with female and male breast cancer: a comparative analysis. BMC Cancer. 2011; 11:335. PMC: 3199869. DOI: 10.1186/1471-2407-11-335. View

13.

Cutuli B, Le-Nir C, Serin D, Kirova Y, Gaci Z, Lemanski C . Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases. Crit Rev Oncol Hematol. 2009; 73(3):246-54. DOI: 10.1016/j.critrevonc.2009.04.002. View

14.

Giordano S, Cohen D, Buzdar A, Perkins G, Hortobagyi G . Breast carcinoma in men: a population-based study. Cancer. 2004; 101(1):51-7. DOI: 10.1002/cncr.20312. View

15.

Patterson J, Battersby L, Bach B . Use of tamoxifen in advanced male breast cancer. Cancer Treat Rep. 1980; 64(6-7):801-4. View

16.

Giordano S, Perkins G, Broglio K, Garcia S, Middleton L, Buzdar A . Adjuvant systemic therapy for male breast carcinoma. Cancer. 2005; 104(11):2359-64. DOI: 10.1002/cncr.21526. View

17.

Siegel R, Ward E, Brawley O, Jemal A . Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61(4):212-36. DOI: 10.3322/caac.20121. View

18.

Agrawal A, Ayantunde A, Rampaul R, Robertson J . Male breast cancer: a review of clinical management. Breast Cancer Res Treat. 2006; 103(1):11-21. DOI: 10.1007/s10549-006-9356-z. View

19.

Zagouri F, Sergentanis T, Koutoulidis V, Sparber C, Steger G, Dubsky P . Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series. Br J Cancer. 2013; 108(11):2259-63. PMC: 3681005. DOI: 10.1038/bjc.2013.255. View

20.

Rudlowski C, Friedrichs N, Faridi A, Fuzesi L, Moll R, Bastert G . Her-2/neu gene amplification and protein expression in primary male breast cancer. Breast Cancer Res Treat. 2004; 84(3):215-23. DOI: 10.1023/B:BREA.0000019953.92921.7e. View